Nano Labs and CIMVA Enter Agreement to Develop Nanotechnologies


Nanotubes imagesNano Labs Corp. is pleased to announce the Company has signed a Non-Disclosure & Confidentiality Agreement with CIMVA (Advanced Materials Research Center) to review, identify, develop and market products based on the industrial application of nanotechnologies and advanced materials.

The Agreement will further Nano Labs’ resources to develop its proprietary nanotechnology and manufacture and produce the Company’s prototypes and products.

The Agreement allows both organizations to cooperatively identify specific joint research and commercial product projects, which will be subject to Specific Agreements outlining the purpose, activities, ownership, and the general rights and obligations of each party.

Each party will retain the copyrights and their respective industrial property rights for any future partnerships, and will outline any new ownership of copyright or industrial property rights generated, produced or resulting from the activities covered in the Specific Agreement(s).

“We are very excited to be working with this esteemed institution. CIMAV has a long history of success. Invention, innovation and commercialization are the heart and soul of this agreement. So much of science today is developed and commercialized on collaboration. Their resources – in terms of technology research infrastructure, human capital and client base – will allow us all to accomplish great things together,” explains Mr. Bernardo Chavarria, President of Nano Labs.

About CIMAV

The CIMAV (Advanced Materials Research Center), participates greatly on three important activities for Mexico. 1. To generate or come up with original basic knowledge and spread it to the national and international scientific community; through worldwide known magazines in the materials, energy, and environmental sectors. 2. To generate human resources for a Master’s Degree and PhD. Level in the materials, energy, and environmental sectors. 3. To transfer the generated knowledge in the organization to the different society sectors.

Since its foundation in October 1994, CIMAV as a CONACYT (National Council of Science and Technology) Public Center, has searched the incorporation of science and technology to society through different ways, just as it has searched for ways to raise the educational level of the human resources. CIMAV, which headquarters is located in Chihuahua, Chihuahua and in Monterrey Unit in Nuevo León state, represents an important effort in decentralizing the scientific and technological activities that are taking place in Mexico, and to spread its benefits to the entire nation.

For more information, please visit http://www.cimav.edu.mx/en/.

Source: http://nanolabs.us/

Nanobiotix Announces EUR 2.8 Million Grant From bpifrance to Accelerate Development of NBTXR3 in a Third New Indication


Through ETPN (European Technology Platform of Nanomedicine), Nanobiotix Is Driving Nanomedicine in Europe and Is Now Involved in the First Nanomedicine Consortium in France With the launch of NICE Project
201306047919620PARIS–(Marketwired – Jul 3, 2013) – NANOBIOTIX (EURONEXT PARIS: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today it has secured c.EUR 9 million in funding from bpifrance (formerly OSEO) of which EUR 2.8 million is directly attributable to the Company. This grant, awarded through bpifrance’s Strategic Industrial Innovation (ISI) program, will accelerate the clinical and industrial development of the Company’s lead product NBTXR3 in a new indication, liver cancer (hepatocellular carcinoma). Liver cancer is a major health problem that causes one of the greatest number of deaths each year worldwide, c.695,000 deaths per annum.

This grant supports the launch of NICE (Nano Innovation for CancEr), the first consortium of nanomedicine stakeholders in France focused on characterization and industrialization aspects. The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France (www.medicen.org).

Consisting of five public and private partners, the NICE consortium includes partners with in depth expertise in the field of nanomedicine. Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for advanced soft tissue sarcoma and has received authorization from the French Medicine Agency, ANSM, to start a second clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer). NBTXR3 will benefit fully from this platform of expertise and funding received from bpifrance by being able to accelerate its clinical development. The purpose of this project is the start of a new Phase I clinical study with NBTXR3 in patients with primary liver cancer.

Watch the Video from Nanobiotix here:

http://www.youtube.com/watch?v=kxSX6YJTS2I&feature=share&list=PL9C30814198614279

In addition to Nanobiotix, the consortium includes BioAlliance Pharma, leader of the consortium which is developing Livatag®, a doxorubicin nanoparticle currently in Phase III clinical trial for treatment of primary liver cancer; CEA-Leti, the developer of cancer-detecting nanoparticles based on Leti’s Lipidots® platform; DBI, a company specialized in the production of nanomedicine pharmaceutical products and the Institut Galien Paris Sud (University Paris Sud/CNRS), which has an academic-excellence team specialized in nanoparticle research.

Today, nanomedicine is considered as one of the major growth drivers of the global pharmaceutical industry and it is essential that the industry is structured at the local level to be competitive,” said Laurent Levy, CEO of Nanobiotix. “In turn, Nanobiotix will benefit from the consortium in two ways; if the sector is structured right to be able to accelerate the development and industrialization of products, and in the development of a new indication of NBTX3 which will help patients and build shareholder value.”

About BPIFRANCE’s Strategic Industrial Innovation (ISI) program

The Strategic Industrial Innovation program promotes the emergence of European champions. It supports ambitious, innovative collaborative projects through to industrialization, driven by innovative medium-sized companies (less than 5000 employees) and small businesses (less than 250 employees). These highly promising projects are aimed at the commercialization of products which result from technological breakthroughs and which not be possible without fostering measures from the public sector. Funding is generally in the EUR 3-10 million range, as grants-in aid and loans which are repayable if the project is a success.

About NANOXRAY

Nanobiotix’s first-in-class, proprietary technology called NanoXray is at the forefront of a new era of nanomedicine, where nanoparticles are not just a vehicle for targeted drug delivery, but have become the principal active element. The NanoXray technology is based on the physical properties of hafnium-oxide nanoparticles and is used to enhance the efficacy of radiotherapy treatment for a variety of cancer indications.

Nanoparticles are designed to enter tumor cells and, upon activation by a standard dose of radiation, they emit large amounts of electrons resulting in the generation of free radicals that destroy cancer cells (the same mode of action than radiotherapy but largely amplified). Nanoparticle-enhanced radiotherapy therefore amplifies the lethal dose of energy locally within the tumor without changing the effect of the dose passing through surrounding healthy tissues.

By changing the coating of the nanoparticles, Nanobiotix is developing three different products that can be administered either by direct injection into the tumor (NBTXR3), intravenous injection (NBTX-IV) or topical application to fill tumor cavities after surgery (NBTX-TOPO). The product applied will depend on type of tumor and the patient’s specific clinical needs. NanoXray products are classified as a medical device in Europe and as a drug in the US. They are compatible with current radiotherapy methods with respect to equipment and protocols, as well as with older radiotherapy equipment or any radiation-based therapy.

About NANOBIOTIX

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France.

Laurent Levy, CEO and co-founder of Nanobiotix, is the Vice-President of the European Technology Platform of Nanomedicine (ETPN).

For more information, please visit www.nanobiotix.com

Press release (PDF): http://hugin.info/157012/R/1714109/569130.pdf

Nano Labs CTLE Literally Redefines “Green Energy”


Press Release: Nano Labs Corp. – Wed, Dec 19, 2012 7:10 AM EST

QDOTS imagesCAKXSY1K 8DETROIT, Dec. 19, 2012 (GLOBE NEWSWIRE) — Nano Labs Corp. (CTLE) today announced it has developed an innovative “intelligent illumination system” for greenhouses, that works with commercial light-emitting diodes (LEDs) to reduce energy consumption and improve processes contributing to the growth of plant life in agricultural greenhouses.

The new system reduces energy consumption while at the same time providing improved control over artificial light used to stimulate photochemical activities in plants for growth and the production of chlorophyll. By employing a “The Pulse Modulated Chlorophyll Fluorescence Monitoring Stage”, the innovative technology provides for the automatic control of light in relation to a whole range of greenhouse and plant conditions, including seasonal adjustments tailored to the type of vegetables and plants being illuminated.

“Through nanotechnology, we believe we’re taking LEDs to another level for commercial greenhouses and the agriculture industry,” said Nano Labs’ President Bernardo Chavarria. ” Our technology offers better control in relation to light frequency (or wavelength), light quality, and pulse width of the light beams emitted by the LEDs, which hold important advantages over other existing artificial illumination sources such as fluorescent lamps, metal halide lamps, and high pressured sodium lamps. Our system offers higher efficiency in terms of energy consumption, quantum efficiency of the light produced, provides longer lifespan, controllable emission spectrum, safer handling, as well as improved disposal procedures.”

In developing the technology, Nano Lab’s goal was to help world agriculture to improve the crop yields and the quality of produce, while maintaining low energy consumption and minimizing the environmental impacts, Mr. Chavaria explained.

“We all know that light, to a large extent, is responsible for life on Earth. However, for a long time Science has worked only to a limited degree to study how we humans can use artificial light to promote plant growth. In recent years, though, we’ve seen very impressive developments in light-emitting diodes (LEDs), not only in terms of their  improved illumination capabilities, but also in relation to affordability. We believe LEDs hold much promise for creating new technologies for the 21st century agriculture,” said Dr. Victor Castano, CEO of Innovation at Nano Labs.

The novel system for greenhouses has allowed Nano Labs to determine the effect of pulsed light, as opposed to simple continuous light, in a frequency range from 0.1Hz to 100 kHz, with red and blue LEDs on the chlorophyll fluorescence emission of tomato plants, demonstrating that it is possible through the Company’s innovations to control and enhance plant growth at will.

This technology represents an answer to the greenhouse growers problem worldwide, of making as efficient as possible the crop yield in their agricultural greenhouses, while maintaining a low energy consumption, thus having a favourable impact on the environment. Also, the technology aims to link two important industrial activities which would seem to have little relation: photonics and agriculture, opening new market opportunities for both. With Nano Labs` approach, it would be possible to increase the vegetable production in greenhouses, independently of the season, for the pulsed LEDs light replicates the crop cycles efficiently at a low energy cost.

About Nano Labs Corp.

Nano Labs Corp. (CTLE) is a nanotechnology research and development company which began during October 2012, but is able to access resources that encompass nearly 30 years of research and development in nanotechnology as well as hundreds of peer-reviewed and published research papers and other scholarly material. The Company’s research and development team of scientists, designers, and engineers is focused on creating a portfolio of advanced products that could provide benefits to a variety of industries including: (i) consumer products, (ii) energy, (iii) materials, and (iv) healthcare. Through the use and integration of proprietary nano compounds, our goal is to evolve common products into new, revolutionary products in order to make the world a better place. Nano Labs shares are traded on the OTC Bulletin Board in the United States under the ticker CTLE. For more information, please visit www.NanoLabs.us.

The Nano Labs Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16293

Forward looking statements

This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those laws. These forward-looking statements are based upon a number of assumptions and estimates that are subject to significant uncertainties that involve known and unknown risks, many of which are beyond our control and are not guarantees of future performance. Actual outcomes and results could materially differ from what is expressed, implied, or forecasted in any such forward-looking statements and any such difference may be caused by risk factors listed from time to time in the Company’s news releases and/or its filings with the OTC Bulletin Board or as a result of other factors.

 

Contact:
Nano Labs Corp. Bernardo Camacho Chavarria President 1 (888) 806-2315

Industrial Nanotech, Inc. Signs Exclusive Agreement with Boral Roofing, LLC


NAPLES, Fla.–(BUSINESS WIRE)–Industrial Nanotech, Inc. (Pink Sheets: INTK), an emerging global leader in nanotechnology based energy saving and sustainable solutions announced today that the Company has signed an agreement granting Boral Roofing, LLC the exclusive rights to market Nansulate(R) Crystal, the Company’s patented clear roof coating, in the US, Canada, Mexico, and the Caribbean. Nansulate(R) Crystal is manufactured and sold exclusively by Industrial Nanotech, Inc.

“We look forward to working with Boral Roofing, LLC to make the benefits of Nansulate(R) Crystal, combined with the extraordinary performance qualities and aesthetic beauty of concrete roof tile, the standard for fine quality roofs”

“We look forward to working with Boral Roofing, LLC to make the benefits of Nansulate(R) Crystal, combined with the extraordinary performance qualities and aesthetic beauty of concrete roof tile, the standard for fine quality roofs,” states Francesca Crolley, VP of Business Development for Industrial Nanotech, Inc.

About Boral Roofing:

Boral Roofing LLC is a subsidiary of Boral USA, the country’s largest premium provider of complete roofing and re-roofing solutions for architects as well as commercial and residential builders. Boral Roofing operates 15 clay and concrete tile manufacturing plants throughout the U.S. and Mexico.

About Boral USA:

Headquartered in Roswell, Georgia, Boral USA is a leading manufacturer in the building material industry. Boral USA’s subsidiaries include Boral Bricks: #1 manufacturer of brick in the United States, Boral Roofing: the nation’s leading manufacturer of clay and concrete roof tiles, Boral Stone Products, manufacturer of Cultured Stone: #1 Brand of manufactured stone veneer, Boral Composites Inc., manufacturer of Boral TruExterior Trim: #1 Brand of poly-ash exterior trim products.

About Nansulate(R)

Nansulate(R) is the Company’s patented product line of award winning, specialty coatings containing a nanotechnology based material that provides the combined performance qualities of thermal insulation, corrosion prevention, resistance to mold growth, chemical resistance and lead encapsulation in an environmentally safe, water-based, coating formulation.

About Industrial Nanotech Inc.

Industrial Nanotech Inc. develops and commercializes new and innovative applications for sustainable nanotechnology which are sold worldwide.